An Open-Label, Two-Part, Dose-Exploration and Multiple Expansion, Phase 2 Study of ONCOS-102 in Combination With Novel Immune-Targeted Anti-Cancer Agents in Patients With Unresectable or Metastatic Cutaneous Melanoma Resistant to Anti-PD-(L)1 Treatment

A Phase 2 study investigating the efficacy and safety of ONCOS-102 alone or in combination with balstilimab (a programmed death receptor-1 [PD-1] inhibitor).

开始日期2024-01-01

申办/合作机构

Targovax Oy

[+1]

NCT02963831 / Completed临床1/2期IIT

A Phase 1/2 Dose Escalation Study With Expansion Cohorts to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

This is a two-part Phase 1/2 dose escalation and dose expansion study of an Adenovirus Vector (Ad5/3-D24-GMCSF), Expressing GM-CSF (GM-CSF-encoding adenovirus), ONCOS-102, in combination with anti-programmed death ligand-1 (PD-L1) antibody, durvalumab, in adult subjects with peritoneal disease who have failed prior standard chemotherapy and have histologically confirmed epithelial ovarian cancer or metastatic colorectal cancer.

开始日期2017-09-07

申办/合作机构

Ludwig Institute for Cancer Research Ltd.

[+3]

NCT03003676 / Completed临床1期

A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After PD1 Blockade

This is a multi center, phase I pilot study of sequential ONCOS-102 and pembrolizumab in patients with advanced or unresectable melanoma progressing after PD1 blockade. The primary objective of the study is to determine the safety of sequential treatment with ONCOS-102 followed by pembrolizumab. The protocol aims to enroll patients into two cohorts: Part I: up to 12 patients will receive sequential treatment with ONCOS-102 followed by pembrolizumab. Part II: up to 12 patients will receive an initial treatment phase with ONCOS-102 followed by a treatment phase with ONCOS-102 in combination with pembrolizumab.

开始日期2016-12-01

申办/合作机构

Targovax Oy

100 项与 ONCOS-102 相关的临床结果

登录后查看更多信息

100 项与 ONCOS-102 相关的转化医学

登录后查看更多信息

100 项与 ONCOS-102 相关的专利（医药）

登录后查看更多信息

项与 ONCOS-102 相关的文献（医药）

2023-09-01·Journal for immunotherapy of cancer

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

Article

作者: Martinez-Marti, Alex ; Ponce, Santiago ; Paz-Ares, Luis ; Navarro, Alejandro ; Vetrhus, Sylvia ; Ricordel, Charles ; Viteri, Santiago ; Isambert, Nicolas ; Jaderberg, Magnus ; Hansen, Thomas Birkballe ; Levitsky, Victor ; Herrera-Juarez, Mercedes ; Cedrés, Susana ; Serres, Xavier ; Lederlin, Mathieu ; Zugazagoitia, Jon

Background:

ONCOS-102, an oncolytic adenovirus expressing granulocyte-macrophage colony-stimulating factor, can alter the tumor microenvironment to an immunostimulatory state. Combining ONCOS-102 with standard-of-care chemotherapy for malignant pleural mesothelioma (MPM) may improve treatment outcomes.

Methods:

In this open-label, randomized study, patients with unresectable MPM received intratumoral ONCOS-102 (3×1011virus particles on days 1, 4, 8, 36, 78, and 120) and pemetrexed plus cisplatin/carboplatin (from day 22), or pemetrexed plus cisplatin/carboplatin alone. The primary endpoint was safety. Overall survival (OS), progression-free survival, objective response rate, and tumor immunologic activation (baseline and day 36 biopsies) were also assessed.

Results:

In total, 31 patients (safety lead-in: n=6, randomized: n=25) were enrolled. Anemia (15.0% and 27.3%) and neutropenia (40.0% and 45.5%) were the most frequent grade ≥3 adverse events (AEs) in the ONCOS-102 (n=20) and chemotherapy-alone (n=11) cohorts. No patients discontinued ONCOS-102 due to AEs. No statistically significant difference in efficacy endpoints was observed. There was a numerical improvement in OS (30-month OS rate 34.1% vs 0; median OS 20.3 vs 13.5 months) with ONCOS-102 versus chemotherapy alone in chemotherapy-naïve patients (n=17). By day 36, ONCOS-102 was associated with increased T-cell infiltration and immune-related gene expression that was not observed in the control cohort. Substantial immune activation in the tumor microenvironment was associated with survival at month 18 in the ONCOS-102 cohort.

Conclusions:

ONCOS-102 plus pemetrexed and cisplatin/carboplatin was well tolerated by patients with MPM. In injected tumors, ONCOS-102 promoted a proinflammatory environment, including T-cell infiltration, which showed association with survival at month 18.

2023-01-04·Clinical cancer research : an official journal of the American Association for Cancer Research

Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma

Communications

作者: Shoushtari, Alexander N. ; Olszanski, Anthony J. ; Hornyak, Thomas J. ; Hansen, Thomas B. ; Nyakas, Marta ; Levitsky, Victor ; Jäderberg, Magnus ; Wolchok, Jedd D. ; Kuryk, Lukasz

Abstract:

Purpose::

Intratumoral oncolytic virotherapy may overcome anti–PD(L)-1 resistance by triggering pro-inflammatory remodeling of the tumor microenvironment. This pilot study investigated ONCOS-102 (oncolytic adenovirus expressing GM-CSF) plus anti–programmed cell death protein 1 (PD)-1 therapy in anti–PD-1–resistant melanoma.

Patients and Methods::

Patients with advanced melanoma progressing after prior PD-1 blockade received intratumoral ONCOS-102 either as priming with 3 doses (3 × 1011 viral particles) during Week 1 [Part 1 (sequential treatment)] or as 4-dose priming and 8 booster doses every 3 weeks [Part 2 (combination treatment)]. From Week 3, all patients received pembrolizumab every 3 weeks (≤8 doses). The primary endpoint was safety. Objective response rate (ORR), progression-free survival, and immunologic activation in repeat biopsies were also investigated.

Results::

In 21 patients (Part 1, n = 9; Part 2, n = 12) ONCOS-102 plus pembrolizumab was well tolerated: most adverse events (AE) were mild/moderate in severity. Pyrexia (43%), chills (43%), and nausea (28%) were the most common ONCOS-102–related AEs. There were no dose-limiting toxicities. ORR was 35% [response evaluation in solid tumors (RECIST) 1.1, irRECIST]. Reduction in size of ≥1 non-injected lesions observed in 53% patients indicated a systemic effect. In injected tumors, persistent immune-related gene expression and T-cell infiltration were associated with clinical benefit. Viral persistence and efficacy in injected and non-injected lesions without additional toxicity supported Part 2 dosing regimen in future studies.

Conclusions::

ONCOS-102 plus pembrolizumab was well tolerated and led to objective responses in patients with anti–PD-1–resistant advanced melanoma. ONCOS-102 promoted T-cell infiltration, particularly cytotoxic CD8+ T cells, which persisted at Week 9, driving clinical benefit. Further investigation of ONCOS-102 plus PD-1 blockade is warranted.See related commentary by Levi and Boland, p. 3

2023-01-04·Clinical cancer research : an official journal of the American Association for Cancer Research

ONCOS-102: A Step Forward or Sideways?

Communications

作者: Levi, Shoshana T. ; Boland, Genevieve M.

Summary:

Treatment of anti–PD-1 refractory melanoma remains a challenge. Intratumoral injection of ONCOS-102, a chimeric oncolytic adenovirus expressing GMCSF, into anti–PD-1–resistant melanoma with administration of pembrolizumab was safe and effective. Response to therapy was associated with increased lymphocyte infiltration and expression of cytotoxicity and costimulatory genes.See related article by Shoushtari et al., p. 100

项与 ONCOS-102 相关的新闻（医药）

2023-01-18

·PRNewswire

Significant Positive Shift in the Malignant Pleural Mesothelioma Market with 5.7% CAGR During the Study Period (2019-2032) Expected by Analysts at DelveInsight

The dynamics of the malignant pleural mesothelioma market are anticipated to change in the coming years owing to the increasing awareness and expected increase in investment in the R&D activities. Companies like AstraZeneca (Imfinzi), Hoffmann-La Roche (Tecentriq (Atezolizumab) Plus Avastin (Bevacizumab), Sellas Life Sciences Group (GALINPEPIMUT-S), PharmaMar (Lurbinectedin, and Trabectedin), and several others are investigating their candidates for malignant pleural mesothelioma treatment. LAS VEGAS, Jan. 18, 2023 /PRNewswire/ -- DelveInsight's Malignant Pleural Mesothelioma Market Insights report includes a comprehensive understanding of current treatment practices, malignant pleural mesothelioma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Key Takeaways from the Malignant Pleural Mesothelioma Market Report As per DelveInsight analysis, the malignant pleural mesothelioma market size in the 7MM was approximately USD 280 million in 2021. According to the assessment done by DelveInsight, the estimated total malignant pleural mesothelioma incident cases in the 7MM were approximately 10.8K in 2021. Globally, leading malignant pleural mesothelioma companies such as Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, Novartis, MolMed, Ys Therapeutics, Merck Sharp & Dohme Corp., Kissei Pharmaceutical Co., Ltd., NovoCure Ltd, AGC Biologics S.p.A, Aduro Biotech, Inc, Bristol-Myers Squibb, Novotech (Australia) Pty Limited, Kyorin Pharmaceuticals, ACADIA Pharmaceuticals, and others are developing novel malignant pleural mesothelioma drugs that can be available in the malignant pleural mesothelioma market in the coming years. The promising malignant pleural mesothelioma therapies in the pipeline include MesoPher, Pegargiminase, Galinpepimut-S (Vaccine), MTG201 + nivolumab, ZEPZELCA (lurbinectedin), IMFINZI, ONCOS-102, TC-210, TECENTRIQ Plus AVASTIN , and others. In December 2022, efficacy and safety data from the phase II/III DENIM trial in Mesothelioma were released by Amphera. In September 2022, Pegargiminase received Fast track status from the US FDA for Mesothelioma. In June 2022, Momotaro-Gene announced that it completed the enrolment in its phase II trial for Mesothelioma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in the USA (Intratumoural). In 2015, the US FDA granted Orphan Drug Designation for MTG-201 for the treatment of malignant mesothelioma. Discover which therapies are expected to grab the major malignant pleural mesothelioma market share @ Malignant Pleural Mesothelioma Market Report Malignant Pleural Mesothelioma Overview Mesothelioma is a rare, aggressive form of malignant tumor that develops in the lining of the lungs, abdomen, or heart after inhaling asbestos fibers. Pleural mesothelioma is a cancer of the pleura, which is the mesothelium that surrounds the lungs. It is the most common type of mesothelioma, accounting for most diagnosed cases. Because men are more likely to be exposed to asbestos, they are more likely to develop mesothelioma. Asbestos exposure is the leading cause of pleural mesothelioma. Asbestos is a mineral group that occurs naturally as bundles of tiny fibers. These fibers can be found in soil and rocks all over the world. Malignant pleural mesothelioma symptoms include chest pain, bloody coughing, difficulty swallowing, dry cough, fluid in the lungs, dyspnea, fever, weight loss, and fatigue. Pleural mesothelioma is frequently diagnosed through a series of tests, including one or more imaging scans, such as an X-ray or CT scan, performed first to identify tumors or metastasis (spreading of disease). Malignant Pleural Mesothelioma Epidemiology Segmentation DelveInsight estimates that there were approximately 10.8K incident cases of malignant pleural mesothelioma in the 7MM in 2021. In the EU5 countries, the highest number of incident cases of MPM was found in the United Kingdom in 2021, followed by Germany and Italy, respectively. The malignant pleural mesothelioma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Incident Cases of Mesothelioma Total Incident Cases of MPM Total Type-specific Cases of MPM Total Incident Cases of MPM Segmented by Age and Gender Total Incident Cases of MPM by Stages Total Treated Cases of MPM Download the report to understand which factors are driving malignant pleural mesothelioma epidemiology trends @ Malignant Pleural Mesothelioma Epidemiological Insights Malignant Pleural Mesothelioma Treatment Market The malignant pleural mesothelioma treatment aims to prolong life, manage symptoms, alleviate pain, and kill cancer cells. When treating malignant pleural mesothelioma, doctors will use a combination of different treatment options to remove as much of cancer as possible. Malignant pleural mesothelioma treatment options currently include chemotherapy, radiation, and surgery. Multimodal therapy refers to the use of multiple approaches by specialists. MPM patients who are diagnosed early benefit the most from surgery. Currently, two main procedures for MPM management are used: pleurectomy and decortication (P/D) and extrapleural pneumonectomy (EPP). Chemotherapy is the most commonly used malignant pleural mesothelioma treatment. Patients with unresectable cancer are frequently treated with palliative systemic chemotherapy. Alimta (pemetrexed) and cisplatin are the most effective combination of mesothelioma drugs. The first drug regimen, nivolumab and ipilimumab, were approved by the US FDA in 2020 for the treatment of adult patients with unresectable malignant pleural mesothelioma. The EMA also approved nivolumab in combination with ipilimumab for the first-line treatment of adult patients with inoperable malignant pleural mesothelioma. Later, in August 2021, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved the combination. To know more about malignant pleural mesothelioma treatment guidelines, visit @ Malignant Pleural Mesothelioma Management Malignant Pleural Mesothelioma Pipeline Therapies and Key Companies MesoPher: Amphera BV Pegargiminase: Polaris Pharmaceuticals Galinpepimut-S (Vaccine): Sellas Life Sciences Group MTG201 + nivolumab: Momotaro-Gene ZEPZELCA (lurbinectedin): PharmaMar IMFINZI: AstraZeneca ONCOS-102: Targovax TC-210: TCR2 Therapeutics TECENTRIQ Plus AVASTIN: Hoffmann-La Roche Learn more about the FDA-approved malignant pleural mesothelioma drugs @ Drugs for Malignant Pleural Mesothelioma Treatment Malignant Pleural Mesothelioma Market Dynamics The dynamics of the malignant pleural mesothelioma market are anticipated to change in the future due to the increasing awareness and expected increase in investment in the R&D activities by the leading pharma companies. In addition, the malignant pleural mesothelioma clinical pipeline is robust, with several therapies in development across a wide range of drug classes/technologies, including monoclonal antibodies, gene therapy, vaccines, and small molecules. Moreover, advances have been made in recent years, such as a better understanding of molecular pathogenesis and the immunological tumor microenvironment. Furthermore, clinical studies investigating systemic therapies for MPM continue to grow. These trials are primarily concerned with immunotherapy, either alone or in combination with other immunotherapies and non-immunotherapies. Thus, significant progress has been made in terms of therapies, pathophysiology, and diagnosis, all of which are expected to contribute to the upcoming malignant pleural mesothelioma market. Furthermore, the frontline setting is still relatively untapped (only a few approved therapies) and can provide lucrative opportunities for several companies to explore the malignant pleural mesothelioma market. However, early detection of MPM is difficult due to the lack of specific symptoms and long latency period (i.e., 20 to 50 years), making current screening approaches ineffective in diagnosing patients at early disease stages, with the majority of patients diagnosed in later or advanced stages. Moreover, the current gold standard of treatment, Alimta, is set to lose malignant pleural mesothelioma market exclusivity in the United States this year, which will significantly impact the sales value of Alimta as well as other emerging drugs in combination with pemetrexed. Thus, these factors will likely to impede the growth of the malignant pleural mesothelioma market. Scope of the Malignant Pleural Mesothelioma Market Report Therapeutic Assessment: Malignant Pleural Mesothelioma current marketed and emerging therapies Malignant Pleural Mesothelioma Market Dynamics: Malignant Pleural Mesothelioma market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Malignant Pleural Mesothelioma Market Access and Reimbursement Discover more about malignant pleural mesothelioma drugs in development @ Malignant Pleural Mesothelioma Clinical Trials Table of Contents Related Reports Malignant Pleural Mesothelioma Epidemiology Forecast Malignant Pleural Mesothelioma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted malignant pleural mesothelioma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Malignant Pleural Mesothelioma Pipeline Malignant Pleural Mesothelioma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key malignant pleural mesothelioma companies, including TCR2 Therapeutics, Hoffmann-La Roche, Novartis, MolMed, Ys Therapeutics, Merck Sharp & Dohme Corp., Kissei Pharmaceutical Co., Ltd., among others. Mesothelioma Market Mesothelioma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key mesothelioma companies, including Amphera, AstraZeneca, Hutchmed, Momotaro-Gene Inc., Sanofi, among others. Mesothelioma Pipeline Mesothelioma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key mesothelioma companies, including Amphera, AstraZeneca, Hutchmed, Momotaro-Gene Inc., Sanofi, among others. Malignant Mesothelioma Market Malignant Mesothelioma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key malignant mesothelioma companies, including Epizyme, Ys Therapeutics, Novartis, Bayer, RS Oncology, among others. Malignant Mesothelioma Pipeline Malignant Mesothelioma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key malignant mesothelioma companies, including Epizyme, Ys Therapeutics, Novartis, Bayer, RS Oncology, among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market Related Healthcare Services Healthcare Business Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

快速通道免疫疗法孤儿药上市批准临床2期

2022-05-31

·GlobeNewswire-Health Care

Agenus Advances Portfolio with 6 Clinical Collaborations

LEXINGTON, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that it has entered into 3 new clinical collaborations with Targovax, Oxford BioTherapeutics, and Immunogenesis, doubling its current number of clinical collaborations. These 6 collaborations span a range of Agenus’ clinical assets, including botensilimab (Fc-enhanced anti-CTLA-4), balstilimab (anti-PD-1), zalifrelimab (anti-CTLA-4), and QS-21 STIMULON™. Agenus is pursuing partnerships with companies developing agents with complementary mechanisms, paving the way for promising immunotherapy combinations to address immunosuppression in the tumor microenvironment. The combination studies are being sponsored and executed by our collaborators, with drug supply and scientific support provided by Agenus. This strategy, enabled by in-house integrated manufacturing and scientific capabilities, positions Agenus to achieve the insights and advances needed to drive development on accelerated timelines. “These new collaborations with Targovax, Oxford BioTherapeutics, and Immunogenesis are exciting next steps in our partnership strategy to broaden combinations and indications under evaluation with our immunomodulatory antibodies,” said Dr. Steven O’Day, Chief Medical Officer at Agenus. “We believe these combinations may unlock the power of immunotherapy more broadly, potentially offering new and promising benefit to patients with treatment-resistant solid tumors.” Agenus’ new and ongoing clinical collaborations are supporting and enabling: Targovax to conduct a clinical trial combining botensilimab and balstilimab with ONCOS-102 (oncolytic virus) in patients with PD-1 relapsed/refractory melanoma. ONCOS-102 is designed to induce immune activation and immunogenic cell death to improve response to immunotherapy.Oxford BioTherapeutics to conduct a clinical trial combining balstilimab with OBT076 (CD205-targeting antibody-drug conjugate) in patients with solid tumors, including lung, gastric, and ovarian cancer. OBT076 is expected to deplete CD205+ cancer cells, and immuno-suppressive cells within the tumor microenvironment, leading to T cell activation and increased response to immunotherapy.Immunogenesis to conduct a clinical trial combining balstilimab and zalifrelimab with evofosfamide (hypoxia-reversal agent) in patients with advanced solid tumors, including prostate, pancreatic, HPV-negative head and neck cancer. Evofosfamide is anticipated to reduce tumor hypoxia and restore T cell infiltration and activity within the tumor microenvironment, increasing responsiveness to checkpoint therapy.Targovax to conduct a clinical trial combining QS-21 STIMULON with TG01 (KRAS vaccine) in up to 3 cancer indications, including multiple myeloma. TG01 is designed to induce T cells that recognize and destroy mut-RAS cancer cells; QS-21 STIMULON is expected to improve immune cell recognition, activation, and TCR diversity of the immune response.Rottapharm Biotech is conducting a clinical trial combining balstilimab with CR6086 (EP4 antagonist) in patients with pMMR-MSS colorectal cancer. CR6086 is expected to inhibit the immune suppressive role of prostaglandins in the tumor microenvironment, improving immunogenicity and responsiveness to immunotherapy. The Phase 1/2 study commenced in 2021.Nelum is conducting a clinical trial combining zalifrelimab with NLM-001 (hedgehog inhibitor) and chemotherapy in patients with advanced pancreatic cancer. NLM-001 in combination with chemotherapy is anticipated to condition the tumor microenvironment to improve T cell infiltration, activation, and responsiveness to immunotherapy. The Phase 1/2 study commenced in 2021. About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter. Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to the use of therapeutic candidates botensilimab, balstilimab, zalifrelimab, and QS-21 STIMULON, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety profile of the therapeutic candidates, both alone and in combination with each other and/or other agents; future clinical and regulatory development plans and commercialization plans for botensilimab, balstilimab, zalifrelimab, and QS-21 STIMULON; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on our website: www.agenusbio.com. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Contact Ethan Lovell, Chief External Affairs & Communications OfficerAgenus Inc.339-927-1763ethan.lovell@agenusbio.com

合作抗体细胞疗法疫苗免疫疗法

2021-11-04

·BioSpace

Targovax ASA: Third quarter 2021 results

OSLO, Norway, Nov. 4, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its third quarter 2021 results. Targovax's CEO will give an online presentation and update on the clinical program to investors, analysts and the press at 10:00 CET today (details below). THIRD QUARTER HIGHLIGHTS Received acceptance of two posters to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November Presented poster at European Society for Medical Oncology (ESMO) Received European Patent for ONCOS-102 in combination with chemotherapy Announced Dr Lone Ottesen's appointment as Chief Development Officer and Ola Melin as Head of Manufacturing POST-PERIOD HIGHLIGHTS In October, Dr. Erik Digman Wiklund was appointed as new Chief Executive Officer. Dr. Wiklund has a strong scientific background in cancer research, and intimate knowledge of the company and its technology having served as Chief Business Officer and Chief Financial Officer of Targovax since 2017. Former CEO Øystein Soug will remain with the company following the appointment of Dr. Wiklund. Mr. Soug will act as a special advisor and also serve as interim CFO providing important strategic and management continuum for the company. KEY FIGURES Erik Digman Wiklund, CEO commented: "Taking over the leadership of Targovax at a time when we have demonstrated a clear signal of efficacy accompanied by a deep biomarker data package for our lead candidate ONCOS-102, is a truly exciting opportunity. The insights we have gained allow us to select the optimal combination strategy for the next development step, as well as to design innovative and differentiated second generation ONCOS vectors to shape our platform for the future." Presentation We invite to a live webcast today at 10.00 CET. You can join the webcast here. It will be possible to ask questions during the presentation. Reporting material TRVX Q3 report.pdf TRVX Q3 presentation.pdf The quarterly report and presentation are also available at the website . For further information, please contact: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@targovax.com Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com Media enquires: Andreas Tinglum - Corporate Communications (Norway) Phone: +47 9300 1773 Email: andreas.tinglum@corpcom.no This information was brought to you by Cision The following files are available for download: View original content: SOURCE Targovax Company Codes: Bloomberg:TRVX@NO, ISIN:NO0010689326, RICS:TRVX.OL, Stockholm:TRVXO

免疫疗法

100 项与 ONCOS-102 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性黑色素瘤	临床2期	-	Agenus, Inc.	2024-01-01
难治性黑色素瘤	临床2期	-	Targovax Oy	2024-01-01
不可切除的黑色素瘤	临床2期	-	Agenus, Inc.	2024-01-01
不可切除的黑色素瘤	临床2期	-	Targovax Oy	2024-01-01
间皮瘤	临床2期	法国	Circio Holding ASA	2018-06-12
间皮瘤	临床2期	西班牙	Circio Holding ASA	2018-06-12
前列腺癌	临床2期	捷克	Excoso as	2018-05-24
阑尾肿瘤	临床2期	美国	MedImmune LLC	2017-09-07
阑尾肿瘤	临床2期	美国	Circio Holding ASA	2017-09-07
结直肠癌	临床2期	美国	MedImmune LLC	2017-09-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02879669 (ASCO2023) 人工标引	临床1/2期	不可切除的胸膜恶性间皮瘤	31	ONCOS-102 + Pemetrexed or cisplatin	襯築簾製繭鏇範窪壓鏇(鑰築糧鹹夢醖鏇鏇衊淵) = 鏇積齋蓋壓鏇憲遞構蓋夢積鏇遞糧鑰構壓淵壓 (餘襯糧衊構艱憲獵製艱 ) 更多	积极	2023-05-31
				Pemetrexed or cisplatin	襯築簾製繭鏇範窪壓鏇(鑰築糧鹹夢醖鏇鏇衊淵) = 製觸糧壓選襯窪鹽壓觸夢積鏇遞糧鑰構壓淵壓 (餘襯糧衊構艱憲獵製艱 ) 更多
NCT02963831 (CTgov)	临床1/2期	卵巢癌 \| 阑尾肿瘤 \| 结直肠癌 ... 更多	67	ONCOS-102+Cyclophosphamide+Durvalumab (Cohort A: ONCOS-102 Dose Escalation)	夢艱網鏇廠衊鏇願鹹襯(鬱簾築窪窪廠鏇構齋遞) = 夢簾獵鏇蓋鹽餘夢夢襯鹽網餘繭積網獵製蓋憲 (遞鏇築顧築窪壓淵鬱膚, 糧獵壓鹹遞製願繭艱壓 ~ 製鹽積遞鏇願鏇鹽廠壓) 更多	-	2022-12-22
				ONCOS-102+Cyclophosphamide+Durvalumab (Cohort 1: Epithelial Ovarian Cancer)	夢艱網鏇廠衊鏇願鹹襯(鬱簾築窪窪廠鏇構齋遞) = 糧鏇醖鏇繭願網鹽積衊鹽網餘繭積網獵製蓋憲 (遞鏇築顧築窪壓淵鬱膚, 膚淵簾鑰糧選餘壓繭築 ~ 廠艱簾築夢衊構顧積膚) 更多
NCT03003676 (615, SITC2022)	临床1/2期	难治性黑色素瘤 GM-CSF-encoding oncolytic adenovirus \| pembrolizumab	21	ONCOS-102	鬱襯夢鏇顧糧範艱觸積(積膚鏇構廠膚淵膚範遞) = 33% 壓遞繭鑰築築艱築糧齋 (繭選繭鏇選壓鬱襯窪窪 ) 更多	积极	2022-11-07
				Pembrolizumab
NCT02963831 (ASCO2022) 人工标引	临床2期	结直肠癌 \| 卵巢上皮癌	-	ONCOS-102+durvalumab (CRC + ITT)	積壓蓋窪顧鑰醖襯壓繭(衊積窪壓鹹醖餘壓範鹹) = occurring in > 30% pts were vomiting, nausea, fatigue, chills, and pyrexia 簾夢築鬱壓夢衊夢襯築 (膚願蓋淵夢鬱願襯顧鏇 ) 更多	-	2022-06-02
				ONCOS-102+durvalumab (OC + ITT)
NCT02879669 (ASCO2022)	临床1/2期	不可切除的胸膜恶性间皮瘤	25	ONCOS-102 + P/C	願鑰範鑰顧淵鹽鹽醖繭(遞衊觸鏇窪獵醖齋艱鏇) = 選淵鏇網簾餘襯窪範觸憲遞淵艱顧製遞齋膚鹹 (鏇艱壓窪鹽蓋顧蓋製窪 ) 更多	-	2022-06-02
				P/C	願鑰範鑰顧淵鹽鹽醖繭(遞衊觸鏇窪獵醖齋艱鏇) = 積蓋鏇齋齋積壓鏇範衊憲遞淵艱顧製遞齋膚鹹 (鏇艱壓窪鹽蓋顧蓋製窪 ) 更多
NCT02879669 (462, SITC2021)	临床1/2期	不可切除的胸膜恶性间皮瘤一线 immune markers	-	ONCOS-102 + pemetrexed/cisplatin	積蓋淵繭觸簾餘範窪鑰(襯繭遞顧夢襯積餘鹽選) = 範壓築鹹窪襯齋積製憲鬱網壓願簾衊遞衊簾齋 (淵壓鹽獵構網顧壓夢艱 ) 更多	积极	2021-11-10
				pemetrexed/cisplatin	積蓋淵繭觸簾餘範窪鑰(襯繭遞顧夢襯積餘鹽選) = 糧選遞願獵築壓憲襯鬱鬱網壓願簾衊遞衊簾齋 (淵壓鹽獵構網顧壓夢艱 ) 更多
NCT03003676 (ESMO2021) 人工标引	临床1期	难治性黑色素瘤	21	pembrolizumab+ONCOS-102	鑰鬱觸襯製淵顧鹹鹽網(製壓遞遞壓窪繭憲廠網) = pyrexia (10%), chills (8%), nausea and hypertension (4%) 願製觸鬱構窪顧襯築醖 (遞憲齋蓋鑰範餘鬱觸膚 ) 更多	积极	2021-09-16
				pembrolizumab+ONCOS-102
NCT03003676 (615 \| ONCOS-102, CTgov)	临床1期	不可切除的黑色素瘤	21	ONCOS-102+Cyclophosphamide+Pembrolizumab (Experimental: ONCOS-102+Cyclophosphamide+Pembrolizumab Part 1)	顧廠糧餘憲廠鑰鹽範糧(願製鏇蓋觸襯製衊鹽衊) = 範遞壓鹽鑰廠範簾艱壓窪鏇蓋築鬱觸製鬱繭範 (蓋觸顧鏇廠製壓壓蓋網, 鹽觸鬱鑰網顧蓋繭襯顧 ~ 壓觸鹹選簾網繭鹽齋憲) 更多	-	2021-08-09
				ONCOS-102+Cyclophosphamide+Pembrolizumab (Experimental: ONCOS-102+Cyclophosphamide+Pembrolizumab Part 2)	顧廠糧餘憲廠鑰鹽範糧(願製鏇蓋觸襯製衊鹽衊) = 憲淵憲鬱艱蓋鏇選遞鹹窪鏇蓋築鬱觸製鬱繭範 (蓋觸顧鏇廠製壓壓蓋網, 顧鑰襯齋壓網襯獵餘觸 ~ 積艱築餘糧網齋衊觸築) 更多
NCT02879669 (361, SITC2020)	临床1/2期	不可切除的胸膜恶性间皮瘤 PD-L1 \| M2 to M1 macrophages	-	ONCOS-102 + pemetrexed/cisplatin	艱顧齋餘觸選獵廠鬱壓(齋簾獵構繭醖膚壓獵選) = 齋鏇製窪鑰繭觸鹹鑰繭淵鏇願窪夢淵夢衊繭鹽 (襯範遞壓鹹膚築選廠顧 ) 更多	积极	2020-12-10
				pemetrexed/cisplatin	艱顧齋餘觸選獵廠鬱壓(齋簾獵構繭醖膚壓獵選) = 蓋製製窪構網窪選襯壓淵鏇願窪夢淵夢衊繭鹽 (襯範遞壓鹹膚築選廠顧 ) 更多
NCT02879669 (PRNewswire) 人工标引	临床1/2期	间皮瘤	31	Standard of Care+ONCOS-102	膚選繭鹹醖獵憲顧窪衊(鏇鹽齋醖範繭鹹積膚鬱) = 醖醖憲顧艱鹽觸齋鏇構鹽衊鹽窪醖廠襯願鹽餘 (網窪窪築觸餘膚衊膚艱 )	积极	2020-11-24
				Standard of Care	膚選繭鹹醖獵憲顧窪衊(鏇鹽齋醖範繭鹹積膚鬱) = 鑰製醖顧鏇餘選遞範艱鹽衊鹽窪醖廠襯願鹽餘 (網窪窪築觸餘膚衊膚艱 )